Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of Oval Cell Marker monoclonal antibody, clone OC2-3C7
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Mouse |
| Host species | Rat |
| Applications | IHC-Fr,IF,Flow Cyt |
More info about Oval Cell Marker monoclonal antibody, clone OC2-3C7
| Brand: | Abnova |
| Reference: | MAB7741 |
| Product name: | Oval Cell Marker monoclonal antibody, clone OC2-3C7 |
| Product description: | Rat monoclonal antibody raised against native oval cell marker. |
| Clone: | OC2-3C7 |
| Isotype: | IgG1 |
| Immunogen: | Native purified oval cell marker from nonparenchymal cells from DDC-treated mice to induce the oval cell response. |
| Form: | Liquid |
| Recommend dilutions: | Flow Cytometry (1:50-1:100) Immunohistochemistry (Frozen sections) (1:100) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In tissue culture supernatant (0.09% sodium azide) |
| Storage instruction: | Store at 4°C. Do not freeze. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Rat |
| Antigen species / target species: | Mouse |
| Specificity: | Specific for both proliferating and normal hepatic periductal cells. |
| Reactivity: | Mouse |
| Application image: |  |
| Application image note: | Immunoflourescent staining of DDC treated mouse liver using Oval Cell Marker monoclonal antibody, clone OC2-3C7 (Cat # MAB7741). |
| Applications: | IHC-Fr,IF,Flow Cyt |
| Shipping condition: | Blue Ice |
| Publications: | Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen.Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, Luk JM, Lee NP, Kwong YL, Au WY, Yuen KY, Lau GK, Liang R. Hepatology. 2008 Aug;48(2):1-10. |